
OncoDaily IO/LinkedIn
Jul 30, 2025, 17:50
New Paper Alert: Perioperative Chemoimmunotherapy In Resectable Stage II–IIIA NSCLC – OncoDaily IO
OncoDaily IO shared a post on LinkedIn:
“New Paper Alert – JAMA Network Open.
Real-world data confirms: Perioperative chemoimmunotherapy significantly improves 18-month distant metastasis-free survival (DMFS) in resectable stage II-IIIA NSCLC.
Yet in 2023, <30% of eligible patients received it.
Key Study Highlights:
- N = 1,334 | Flatiron Health EHR database
- DMFS:
- Neoadjuvant: 80.2%
- Adjuvant: 83.0%
- DMFS ≥95% when ≥12 months of adjuvant immunotherapy is completed
Challenges Identified:
- Underutilization in real-world settings
- Suboptimal biomarker testing (<60% in neoadjuvant cohort)
- Variability in treatment duration
Urgent need for:
- Improved biomarker testing workflows
- Greater multidisciplinary uptake
Read the full study: Desai et al, JAMA Network Open, June 2025.
Summary.“
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 30, 2025, 17:38
Jul 30, 2025, 17:34
Jul 30, 2025, 17:31
Jul 30, 2025, 17:25
Jul 30, 2025, 17:24
Jul 30, 2025, 17:17
Jul 30, 2025, 16:58
Jul 30, 2025, 16:42